Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-07-31

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to develop a measurement of walking quality, called Gait Deviation Index (GDI) for people with Multiple Sclerosis (MS).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

At-Home Gait Assessment

NCT05724901

Multiple Sclerosis

COMPLETED

Validation of a Smartphone-based Assessment of Movement Health

NCT04854148

Mobility Limitation

UNKNOWN

Investigation of Gait Parameters in Health and Neurological Disease Under Varying Locomotor Conditions

NCT02165787

Gait Analysis in Neurological Disorders

COMPLETED

Quantified Balance Measures During Stance and Gait: Multiple Sclerosis Patients. A Longitudinal Clinical Study

NCT02142946

Balance Control

RECRUITING

Measurement and Training of Dual-Task of Gait in Persons With Multiple Sclerosis

NCT03536299

Multiple Sclerosis Gait Disorders, Neurologic Cognitive Impairment

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In rehabilitation in general, in order to track patients' progress and provide next steps, there is a need for easily obtainable, understandable, and objective measures of ability. Currently, there is no measure that clinicians can utilize to determine walking quality. While Gait Deviation Index has been validated and can reliably be used in adults who experienced a Spinal Cord Injury, it has not yet been validated in people with MS. After the MS-specific GDI is developed from this study, therapists and clinicians will be able use it as a reliable progress measure. Which may lead to the delivery of more effective therapy for patients with MS.

Here we plan to measure body position with camera based tracking during your gait cycle.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Relapse Multiple Sclerosis, Relapsing-Remitting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observation

Gait quality observation

Camera Based Kinematic Analysis

Intervention Type DIAGNOSTIC_TEST

Observational Study using Camera Based, Marker Less Kinematic Analysis of gait quality of persons with Multiple Sclerosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Camera Based Kinematic Analysis

Observational Study using Camera Based, Marker Less Kinematic Analysis of gait quality of persons with Multiple Sclerosis

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

OpenCap

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of relapsing form of MS (including relapsing-remitting MS and secondary progressive MS)
* Able to ambulate overground
* Relapse free for at least 1 month
* Age ≥18 and ≤ 75 years
* Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening